Enfortumab Vedotin
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Urothelial Carcinoma
Conditions
Metastatic Urothelial Carcinoma
Trial Timeline
Jun 21, 2025 → Dec 31, 2027
NCT ID
NCT06862219About Enfortumab Vedotin
Enfortumab Vedotin is a approved stage product being developed by Astellas Pharma for Metastatic Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06862219. Target conditions include Metastatic Urothelial Carcinoma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07139977 | Phase 2 | Recruiting |
| NCT07347314 | Phase 2 | Recruiting |
| NCT06862219 | Approved | Recruiting |
| NCT06891560 | Phase 2 | Recruiting |
| NCT06553885 | Phase 2 | Recruiting |
| NCT06394570 | Phase 1/2 | Recruiting |
| NCT06011954 | Pre-clinical | Recruiting |
| NCT05868265 | Phase 2 | Recruiting |
| NCT04754191 | Phase 2 | Active |
| NCT05014139 | Phase 1 | Terminated |
| NCT04995419 | Phase 2 | Completed |
| NCT03219333 | Phase 2 | Completed |
| NCT03070990 | Phase 1 | Completed |
| NCT02091999 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Urothelial Carcinoma